MAPT and Alzheimer disease: As discussed in a recent systematic review of MCI [7], a number of factors have been suggested to further predict conversion to AD in MCI patients, and it is becoming increasingly evident that biomarkers, such as cerebrospinal fluid (CSF) markers including beta-amyloid1-42 and total tau protein, may have a good accuracy for identifying impending AD in MCI patients [14] compared to healthy controls.